chrisvoncsefalvay/vaers-outcomes huggingface dataset:
In the afternoon following shots, pt developed diarrhea & fever of 101F. Mom reports fever got as high as 103F. Decreased appetite, as well, starting afternoon following shots. Diarrhea subsided. Day after shots still has low appetite & T 101 in am of 5/27/10 per mom.
Vaccine administered 6/2/23  expired on  5/30/23. I have a case number with Moderna, they are checking the data to check the viability of the vaccine. Case# MI-00030447
No adverse event; Vaccine administered after BUD; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine administered after BUD) and NO ADVERSE EVENT (No adverse event) in a 22-month-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1414B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 19-Jul-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Jul-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine administered after BUD). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine administered after BUD) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Vaccine administered after BUD).     Concomitant medication was not provided.  Vaccine was received at vaccination centre on 07-Jun-2022 and before use date was reported as 07-Jul-2022.  Treatment information was not reported.
patient reported feeling lightheaded and becoming short of breath and wheezing.  Patient appeared to have lost consciousness with rapid breathing.  Patient woke up after 5 mins, took 2 puffs of albuterol and states she felt fine.
Weird swelling blisters on the left side of he lip; Swelling blisters on left side of lip; This spontaneous case was reported by a consumer and describes the occurrence of BLISTER (Weird swelling blisters on the left side of he lip) and SWELLING (Swelling blisters on left side of lip) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for an unknown indication.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, the patient experienced BLISTER (Weird swelling blisters on the left side of he lip) and SWELLING (Swelling blisters on left side of lip). At the time of the report, BLISTER (Weird swelling blisters on the left side of he lip) and SWELLING (Swelling blisters on left side of lip) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication included birth control.  No treatment information was provided.
This case is linked to the case# 2013-08055 (sister's case received from same reporter and same product). Initial information received from a healthcare professional on 09 September 2013. A male patient had received a dose of DAPTACEL (0.5 ml, batch number C42111AA, dose number- 5) intramuscularly in the right lateral thigh, on 18 October 2011. The patient had severe food allergies in past. The patient's other medical history and concomitant medications were not reported. It was reported that the component of Dtap Stainer-Scholte liquid medium, source was under investigation as children are highly allergic to nuts, eggs, cow's milk, gluten and other foods. On an unspecified date, after vaccination, the patient experienced swelling in the injected leg and the patient also had symptomology of eczema. Laboratory investigations and corrective treatment was not reported. At the time of this report, the outcome of the adverse event was not reported. Documents held by sender: none. The follow up information received from a healthcare professional on 25 October 2013: The patient received IPV (dose unknown, batch number- G108321, dose number- 3) intramuscularly in the left lateral thigh, on 18 October 2013. The patient did not receive any other medications. The patient had no illness at the time of vaccination. Events eczema and vaccination site swelling were recovered at the time of this report.
Extreme pain in shoulder and left arm within two hours of receiving injection. On August 16, received a ketorolac injection for pain and aching, On October 14, received an injection of cortisone and a diagnosis of adhesive capsulitis of left shoulder (frozen shoulder). On October 31, I saw a doctor and was given an MRI that confirmed "frozen shoulder". I have an appointment to see an orthopedic specialist on November 24, 2017. I must note that I had no problems with my left shoulder/arm prior to this injection.
This case was reported by a physician via call center representative and described the occurrence of headache in a female patient who received SHINGRIX for prophylaxis. On 4th October 2018, the patient received SHINGRIX. On 6th October 2018, 2 days after receiving SHINGRIX, the patient experienced headache, fatigue, muscle weakness, joint pain and tingling feet/hands. On an unknown date, the outcome of the headache, fatigue, muscle weakness, joint pain and tingling feet/hands were unknown. It was unknown if the reporter considered the headache, fatigue, muscle weakness, joint pain and tingling feet/hands to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient received a dose of SHINGRIX on Thursday. The patient woke up on Saturday with severe headache, joint pain, tingling in her fingers and toes, loss of muscle strength and severe fatigue. The patient was in bed since Saturday. The patient described these adverse events as grade 3. The patient was basically bed-bound. No additional information could be obtained because the physician was in a rush.
Aside from previous reactions reported through v safe, today I had a reaction to the injection site about the size of a softball that is slightly painful, moderately itchy, hot to the touch, firm and swollen.
cold; headache; chills; wheezing; having difficulty catching her breath/ little shortness of breath/ I couldn't breath; woke up; I couldn't breath it was like a panic attack or something but I couldn't breath; This is a spontaneous report from a contactable consumer This 68-year-old female consumer (patient) reported for herself that who received COMIRNATY, COVID 19 Vaccine, mRNA, solution for injection, dose 2 (Lot Number: EN6198 expiry date was unknown) via an unspecified route of administration on 06Mar2021 10:00 (at the age of 68-years-old) as dose2, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. historical vaccine BNT162B2 (BNT162B2) dose 1 solution for injection, (lot number and expiry date was unknown) via unspecified route of administration on an unspecified date as first dose single for COVID-19 immunisation. Concern: Consumer Stated, "she has a question about the booster. Do you think that you can answer for her? She (Incomplete Sentence). Her fully vaccinated; she has her first and second shot. She over 65, what her concerned about she don't know if she need to be but before she take the booster she wanted to ask a question she after received her second shot she think she took it may be around 10 o'clock in the morning and she have to sit for about 15 minute and then after she left, may be around 1 am in the morning, she start to have Chills, she can't get warm she started to like she guess she couldn't breathe she was having like shortness of breath wheezing and little shortness of breath and of course she had a Headache the next day but this happened to be like 1 o'clock at night it happened after she took her last shot so, her little bit concerned she am not so much as concerned about chill, the effect of chill she was just like she felt like she couldn't breathe it was like a panic attack or something but she couldn't breath and she was wondering if she take the booster, her little bit afraid if what may she have if that considered a side effect or it considered what could happen with the vaccine. Paraphrased the concern: Consumer Stated, "Well, she wanted to take it but her concerned about she doesn't want the breathing like issue like she felt that particular night but its finally went away. Consumer was informed about the Role of Pfizer drug safety and medical information. When asked permission for filing a safety report, consumer Stated, "Okay she don't, do she have to report, or do she just need to talk to someone in the medical department? consumer stated, "she just like to talk, she would just like to talk to someone in the medical department. Vaccine Name: COVID-19 Vaccine. Consumer was informed about Pfizer Medical information department and was provided with the number as # and was informed about the timings as 8 AM-8 PM Monday to Friday. As, consumer was unwilling to complete the report. further probing could not be done. Hence, limited information available over the call. Outcome of the events was cold, middle insomnia, was unknown headache was not recovered, all other events was recovered 07Mar2021 03:00
Patient called me (the pharmacist) Sat 10 am (about 24 hours post injection) complaining of skin that was hot to the touch, swollen and the swelling was continuing to spread.  She was concerned.  She has a history of one bad reaction to tetanus vaccine that required medical care several years ago, she mentioned the same really big swelling during our consult on Friday.  On Friday we discussed her history and since it was a different vaccine and she had no problems with influenza or Pneumovax, she elected to get the Zostavax.  I suggested she circle the current swelling zone in permanent marker and then find a ride to urgent care to get checked out.  As of right now, no shortness of breath reported.
Fatigue, brain fog, mild fever (100), sore/achy muscles, difficulty breathing in fully. Arm of injection hurts to lift
runny nose; lost sense of taste; This spontaneous case was reported by a consumer and describes the occurrence of RHINORRHOEA (runny nose) and AGEUSIA (lost sense of taste) in an 87-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, the patient experienced RHINORRHOEA (runny nose) and AGEUSIA (lost sense of taste). At the time of the report, RHINORRHOEA (runny nose) and AGEUSIA (lost sense of taste) outcome was unknown. Not Provided          No concomitant medications were reported. Treatment details were not reported.
Started fever 6 hours after injection.  Tylenol given.Fussy. Appetite down and remains down.  Awoke whimpering with high fever (10 pm) Temp Rectal 105.1.  Left leg with red area that has increased in size at site of injection.  Still red today, still remains fussy, not sleeping or eating well. Fever persists but not as high.
Pt. tolerated inject well approx. 10 min after reported he had double vision, could see gray shadow 6 in around objects. Given water and juice for hydration. No other symptoms. Vital signs stable. After resting 40 min. shadow reduced to 3 inches around object. Total time in office 80 min. APRN checked pt sent home to rest. Mom reports vision issue gone upon waking from nap 3:30 pm.
Information has been received from Sanofi Pasteur MSD (manufacturer control # 2016008857) as a part of a business agreement on 06-SEP-2016. Case received from a physician via HA on 01-Sep-2016 under reference numbers DK-DKMA-WBS-0004375 / DK-DKMA-ADR 23625530. A 24-year-old female adult patient received GARDASIL, (batch number Not available, Dose 1) via intramuscular route on 14-Jul-2010, GARDASIL, (batch number Not available, Dose 2) via intramuscular route on 15-Oct-2010, GARDASIL, (batch number Not available, Dose 3) via intramuscular route on 23-Aug-2011. The patient experienced Abdominal pain on 04-Sep-2011 12 days Post Administration, Headache on 04-Sep-2011 12 days Post Administration, Dizziness on an unknown date, Nausea on an unknown date, Diarrhea on an unknown date, Obstipation on an unknown date, Skin disorder on an unknown date, Fatigue on an unknown date, Concentration loss on an unknown date, weakness of leg / weakness of arms on an unknown date, Bloated feeling on an unknown date, Irritable colon on an unknown date, Neuropathic pain on an unknown date, Influenza like illness on an unknown date, Chills on an unknown date, Difficulty focusing eyes on an unknown date, Palpitation on an unknown date, Lactose diarrhea on an unknown date, Light sensitivity on 04-Sep-2011 12 days Post Administration and Fever on 04-Sep-2011 12 days Post Administration. The patient reports that the first symptoms started 14 days after the third vaccination, with fever, abdominal pain, headache, sensitivity to light. Also flu-like symptoms. These episodes are continuous and occur periodically. Can last 3 days, morning and evenings are the worst - 3 day break - 3 days with symptoms and so on. In Autumn and Winter, she is almost constantly sick. Before the vaccines she ran 3 times a week and did strength training. Was employed as a junior producer in the film industry, but had to stop due to her diseases. The tilt table test showed that she does not fulfill the diagnostic criteria for Postural Orthostatic Tachycardia Syndrome. Other vaccines: No. Other medicines: No. The patient's outcome was reported as Not Recovered/Not Resolved.
On 9/30/16, This 4 yo C/U with MMR-V and KINRIX administered. . On 9/30/16, as per Mother, pt has pain and mild swelling at (L) thigh. On 10/02/16, area spread and was red, hot, hard and painful. Pt. developed fever (and chills) and spiked to 104 degree F overnight. Pt also C/O stomach ache and throat pain. 10/03/16 - on exam (L) Anterior thigh redness + 71/2 in ling x 8 in medially to anterior lateralis.
Atypical Pneumonia and Costochondritis, Tachycardia, Tachypnea, Fever resulting in hospitalization - cefTRIAXone, ibuprofen, Lovenox, symptoms abated within 48 hours.  I believe this to be unrelated to the vaccine.
Flu-like symptoms; Chills; Fever; Body ache; Joint pain; Headache; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu-like symptoms), CHILLS (Chills), PYREXIA (Fever), MYALGIA (Body ache) and ARTHRALGIA (Joint pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history reported by reporter.  Concomitant products included ATORVASTATIN, ACETYLSALICYLIC ACID (ASPIRIN 81) and COLECALCIFEROL (VITAMIN D [COLECALCIFEROL]) for an unknown indication.   On 28-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu-like symptoms), CHILLS (Chills), PYREXIA (Fever), MYALGIA (Body ache), ARTHRALGIA (Joint pain) and HEADACHE (Headache). At the time of the report, INFLUENZA LIKE ILLNESS (Flu-like symptoms), CHILLS (Chills), PYREXIA (Fever), MYALGIA (Body ache), ARTHRALGIA (Joint pain) and HEADACHE (Headache) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 01-Jun-2021: Follow-up information received on 01-Jun-2021 contains new information.
Third does of Pfizer vaccine. This was my first booster shot. Experienced onset of Tinnitus in right ear that has not gone away. The ear, nose and throat doctor could not cure it. Ear tests suggested long term, chronic tinnitus and slight hearing loss. This was likely caused by the vaccine. There was no trauma to my right ear prior to the onset of tinnitus other than the vaccination.
My adverse event started on 02/05/2023. I had head and chest cold. I have cough, slight fever,  sinus and voice loss following chest congestions.  On 02/05/2023 in the morning at around 03:30AM I went to the ER. They mentioned that chest congestions created a problem for my throat to close up. They prescribed me 10 day supply of Sudafed and Steroid shot. They also  did a X-RAY which was negative. I was tested for COVID-19 and FLU swab which were negative. They advised me to follow up with my doctor. I will be going an ENT on  03/28/2023.
Patient received a FLUARIX QUAD vaccine on 10/26/16 approximately 2:30 pm. Patient returned and said she was suffering from chills and nausea.
Feeling numbness at site of injection; Finger tingling; Feeling sweaty (Hot); A spontaneous report was received from a nurse, concerning a 52-year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced numbness at vaccine site of injection, finger tingling and feeling sweaty (hot).  The patient's medical history was not provided. Products known to have been used by the patient, within two weeks prior to the event, included sertraline hydrochloride, multivitamins, vitamin D, vitamin B12, collagen and flaxseed oil.    On 28-Dec-2020, prior to the onset of the event, the patient received their first of two planned doses of mRNA-1273 (Lot number: 026L20A) intramuscularly in her right arm for prophylaxis of COVID-19 infection.  The nurse reported that within 30 minutes after receiving the vaccination, the patient stated that the arm where she got the injection was feeling in numbness and that her finger was tingling. The nurse reported that there was no redness or swelling. The reporter stated that the patient felt hot (sweaty). No treatment was given.  Action taken with mRNA-1273 in response to the events was unknown.   The outcome of the events, numbness at vaccine site of injection, finger tingling, and feeling sweaty (hot), were considered unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
CLIENT CAME IN AT 8:00 AM WITH A 50 CENT SIZE REDDENED AND SLIGHTLY SWOLLEN AREA ON LEFT ARM (UPPER ARM). ADVISED USING A COOL COMPRESS TO THE ARE FOR FIRST 24 AND THEN SWITCH TO A WARM COMPRESS.
This case was reported by a consumer via call center representative and described the occurrence of diarrhea in a 23-year-old female patient who received RABAVERT. The patient's past medical history included animal bite (she was bitten on her back by a bat). On 13th November 2017, the patient received the 1st dose of RABAVERT. In November 2017, less than a week after receiving RABAVERT, the patient experienced diarrhea and vomiting. On an unknown date, the outcome of the diarrhea and vomiting were unknown. It was unknown if the reporter considered the diarrhea and vomiting to be related to RABAVERT. Additional details were reported as follows: The reporter was the patient's mother. The reporter was an employee of the facility where the vaccine was given to her daughter and because the mother was questioning the process and how the vaccine was given. The reporter had been told by hospital administrator's she was causing trouble. The reporter noted the bat was not caught and was trying to just be an advocate for her daughter. She stated she was told by site manager of facility that the manufacturer had been contacted and everything was fine. This was 1 of 3 cases, reported by same reporter for same patient.
hard red lump, hot at the injection site; hard red lump, hot at the injection site; pain; headache; redness around edges, purple at injection site with another ring like a bulls eye; redness around edges, purple at injection site with another ring like a bulls eye; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (hard red lump, hot at the injection site), VACCINATION SITE INDURATION (hard red lump, hot at the injection site), VACCINATION SITE DISCOLOURATION (redness around edges, purple at injection site with another ring like a bulls eye), VACCINATION SITE PAIN (pain) and VACCINATION SITE ERYTHEMA (redness around edges, purple at injection site with another ring like a bulls eye) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Headache.    On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, the patient experienced VACCINATION SITE DISCOLOURATION (redness around edges, purple at injection site with another ring like a bulls eye) and VACCINATION SITE ERYTHEMA (redness around edges, purple at injection site with another ring like a bulls eye). On an unknown date, the patient experienced VACCINATION SITE WARMTH (hard red lump, hot at the injection site), VACCINATION SITE INDURATION (hard red lump, hot at the injection site), VACCINATION SITE PAIN (pain) and HEADACHE (headache). At the time of the report, VACCINATION SITE WARMTH (hard red lump, hot at the injection site), VACCINATION SITE INDURATION (hard red lump, hot at the injection site) and VACCINATION SITE PAIN (pain) had resolved and VACCINATION SITE DISCOLOURATION (redness around edges, purple at injection site with another ring like a bulls eye), VACCINATION SITE ERYTHEMA (redness around edges, purple at injection site with another ring like a bulls eye) and HEADACHE (headache) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication reported  No treatment information was provided
Red , slightly itchy rash started one week after the vaccine. Rash is around the injection site, oval in shape, about 2 inches long. 2 days later a white spot developed within the rash.
cough; Got flu type A; Initial information was received on 26-Dec-2022 regarding an unsolicited valid Social Media non-serious case received from a consumer/non-health-care professional.  This case involves unknown age and gender patient who experienced cough and got flu type a after receiving influenza vaccine.  The patient's past medical history included COVID-19 in september. The patient's past medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date and year in October, the patient received an unknown dose of suspect influenza vaccine produced by unknown manufacturer (unknown formulation) (lot number, expiry date, strength, frequency was unknown) via intramuscular route in unknown administration site for Influenza immunization.  On an unknown date the patient developed a non-serious event of events cough and got flu type a (influenza) (unknown latency) following the administration of influenza vaccine.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events.  At time of reporting, the outcome was Unknown for the events.
patient was fainted for couples of minutes after 10 minutes of the pfizer shot.  Her face was pale.  She was slowly gaining her consciousness.  She was giving juicy to drink and seemed getting back to normal after 10-15minutes.  Patient felt totally fine when she left the pharmacy